Infraredx, Inc. news
Dr. Giulio Guagliumi from ASST Papa Giovanni XXIII in Bergamo, Italy discusses the “use of IVUS+NIRS imaging for decision making in acute coronary syndrome,” during the 2020 EuroPCR e-course. The course discusses:
- The frequency of culprit lesion ambiguity in ACS
- The value of IVUS+NIRS imaging in challenging scenarios
- Integrating the information provided by IVUS+NIRS imaging in the clinical decision-making process.
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study (NCT04985773) at the Cardiology Associates of North Mississippi in Tupelo, Mississippi. The study will be conducted in the United States with the objective to evaluate safety and effectiveness of the Lacrosse NSE (Non-Slip Element) ALPHA coronary dilatation balloon catheter during percutaneous coronary intervention (P
Nipro Medical Corporation (NMC), a leading Renal, Medical, Surgical, and Interventional Radiology products manufacturer, announces the creation of a Vascular Division in the U.S. The division will include several cutting-edge technologies, innovative vascular and cardiovascular products to provide clinicians with procedural and imaging solutions that enhance patient care. To support the new product portfolio, NMC is hiring Account Executives in multiple locations across the country.
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the indications for use for its Makoto Intravascular Imaging System. The approval is based on the results of the landmark Lipid-Rich Plaque (LRP) Study, which demonstrated the ability of intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) technology to identify pati
Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, presented late-breaking clinical trial results for its landmark Lipid-Rich Plaque (LRP) Study today at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. Cardiovascular disease remains the number one cause of death globally, accounting for 31 percent of deaths,1 and despite optimal medical therapy and risk modification strat